Clinical Trial

ABY-029 Glioma Trial

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach brain tumors so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-02; most recent amendment 2026-03-07.
Status change: Not Yet Recruiting → Recruiting 2026-03-07
Trial Details
NCT Number NCT07063693
Lead Sponsor Dartmouth-Hitchcock Medical Center
Collaborators: Dartmouth College, National Cancer Institute (NCI)
Conditions Intracranial Tumor
Enrollment 33 participants
Start Date 2026-02-17
Primary Completion 2028-07-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-10